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Background: The hemodynamic responses to endotracheal intubation are associated with sympathoadrenal activity. 
Polymorphisms in the beta1-adrenergic receptor (β1AR) gene can alter the pathophysiology of specific diseases. The 
aim of this study is to investigate whether the Ser49Gly and Arg389Gly polymorphism of the β1AR gene have different 
cardiovascular responses during endotracheal intubation under sevoflurane anesthesia. 
Methods: Ninety-one healthy patients undergoing general anesthesia were enrolled. Patients underwent slow 
inhalation induction of anesthesia using sevoflurane in 100% oxygen. Vecuronium 0.15 mg/kg was given for muscle 
relaxation. Endotracheal intubation was performed by an anesthesiologist. The mean arterial pressure (MAP), 
heart rate (HR), and the corrected QT (QTc) interval were measured before induction, before laryngoscopy, and 
immediately after tracheal intubation. Genomic DNA was isolated from the patients’ peripheral blood and then 
evaluated for the β1AR-49 and β1AR-389 genes using an allele-specific polymerase chain reaction method. 
Results: No differences were found in the baseline values of MAP, HR, and the QTc interval among β1AR-49 and 
β1AR-389, respectively. In the case of β1AR-49, the QTc interval change immediately after tracheal intubation was 
significantly greater in Ser/Ser genotypes than in Ser/Gly genotypes. No differences were observed immediately after 
tracheal intubation in MAP and HR for β1AR-49 and β1AR-389. 
Conclusions: We found an association between the Ser49 homozygote gene of β1AR-49 polymorphism and increased 
QTc prolongation during endotracheal intubation with sevoflurane anesthesia. Thus, β1AR-49 polymorphism may be 
useful in predicting the risk of arrhythmia during endotracheal intubation in patients with long QT syndrome. (Korean 
J Anesthesiol 2011; 61: 117-121)
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Introduction
    Endotracheal intubation using laryngoscopy increases arterial 
pressure, heart rate, and the incidence of cardiac arrhythmias, 
which usually cause little consequence in healthy patients but 
may be detrimental to patients with cardiovascular diseases [1-3]. 
The hemodynamic responses to laryngoscopy and tracheal 
intu  bation are caused by a catecholamine discharge associated 
with sympathoadrenal activity. The corrected QT (QTc) interval 
can also be prolonged during rapid injection of catecholamine, 
brief stimulation of the sympathetic nervous system, and an 
imbalance of the cardiac sympathetic tone [4-7]. 
    Stimulation of the sympathetic nervous system, due to 
exercise or emotional stress, causes activation of cardiac 
β-adrenoceptors. Beta1-adrenergic receptor (β1AR) is an 
important mediator of the sympathetic cascade and regulates 
numerous physiologic events, including heart rate and 
contractility. Polymorphisms in the β1AR gene can affect 
responses to drugs in patients with hypertension or heart failure 
and alter the pathophysiology of specific disease states, where 
sympathetic activation plays a major role. The β1AR gene is 
localized to chromosome 10 and two common polymorphisms, 
Ser49Gly and Arg389Gly, were identified in 1999 [8]. 
    The Ser49Gly polymorphism is located in the extracellular 
amino-terminal region of the receptor and the Gly49 variant 
correlates with the development of cardiomyopathy and 
heart failure [9,10]. Arg389Gly is located in the intracellular 
cytoplasmic tail near the seventh transmembrane region of 
the receptor, which is a putative Gs-protein binding domain. 
Patients homozygous for the Arg389 allele are at an increased 
risk for developing hypertension [11]. Given these findings, 
endogenous catecholamine stimulation of β1AR during 
endotracheal intubation may result in enhanced cardiovascular 
response in one genotype over another. No study has been 
made on β1AR polymorphism with cardiovascular responses to 
endotracheal intubation under laryngoscopy. 
    The aim of the present study is to investigate whether the 
functionally important Ser49Gly polymorphism and the 
Arg389Gly polymorphism of the β1AR gene have different 
cardiovascular responses during endotracheal intubation under 
sevoflurane anesthesia. 
Materials and Methods
    After obtaining approval from our Institutional Review Board 
and receiving written informed consent from the participants, 
100 patients (American Society of Anesthesiologists physical 
status class 1) between the ages of 20 and 50 were enrolled in 
this study. Patient exclusion criteria were: abnormal serum 
electrolyte values, a QTc interval duration greater than 440 
ms, taking medication affecting QTc interval duration (tricylic 
antidepressant agents, antidysrhythmics, beta adrenergic 
antagonists, calcium channel blocking agents), the existence 
of valvular cardiac disease, and any cardiac rhythm other than 
sinus rhythm, diabetes mellitus, pregnancy, or obesity. 
    All study data were collected in the morning (8:00-11:00) to 
prevent the effects of day-night changes on the QTc interval. 
Patients received no premedication. After being taken into the 
operating room, electrocardiogram monitoring, pulse oximetry, 
non-invasive blood pressure, fraction of inspired oxygen and 
end-tidal sevoflurane, and carbon dioxide concentration 
monitoring were begun. Blood pressure was measured with 
an auto  matic oscillographic device every 2 minute during 
the study period. After the monitoring equipment had been 
attached, the patients were allowed to rest for 5 minutes 
while lactated Ringer’s solution 4 ml/kg was infused before 
inducing anesthesia. A standard real-time automated three-
lead electrocardiogram was continuously recorded using a 
data acquisition system (PowerLab; AD Instruments, Colorado 
Springs, CO, USA). The QT interval was measured in lead II from 
the onset of the QRS complex to the end of the T wave, which 
was defined as a return to the T-P baseline. When U waves were 
present, the nadir between the T and U waves was regarded as 
the end of the QT interval. Biphasic T waves were considered 
to end with the final return to baseline. The values of the QT 
interval of four successive beats were averaged. The QT interval 
was corrected using the Fridericia formula: QTc = QT / 
3√(R - R 
interval).
    Patients underwent slow inhalation induction of anesthesia 
with a facemask using sevoflurane in 100% oxygen to avoid 
the confounding effects of other anesthetic agents. Anesthesia 
was induced by initially administering 1.0% sevoflurane and 
increasing the inspiratory concentration after every fifth breath 
by 0.5% until a maximum of 6% sevoflurane was reached. After 
induction, the anesthesia was maintained with sevoflurane 
and ventilation was assisted using a facemask at an end-tidal 
concentration of 3% sevoflurane to provide an adequate depth 
of anesthesia. As spontaneous breathing diminished, patients 
were manually assisted via the facemask while an exhaled 
tidal volume of 8 ml/kg was maintained. The respiratory rate 
was adjusted to maintain an end-tidal carbon dioxide partial 
pressure of 35 mmHg. Vecuronium 0.15 mg/kg was given for 
muscle relaxation at 10 min after induction with sevoflurane. 
Laryngoscopy was attempted 5 min after vecuronium injection. 
Laryngoscopy and tracheal intubation were performed by 
one anesthesiologist, and then the sevoflurane end-tidal 
concentration was reduced to 2%. Data for patients with a failed 
intubation on the first attempt or intubations which took more 
than 40 sec were also excluded from the analysis. The mean 
arterial pressure (MAP), heart rate (HR), and QTc interval were 119 www.ekja.org
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measured before induction, before laryngoscopy, and immedi-
ately after tracheal intubation. 
    All patients underwent peripheral blood sampling for 
isolation of genomic DNA. Samples were stored at -20
oC until 
DNA extraction. Genomic DNA was prepared using a nucleic 
acid isolation device, QuickGene Mini-80 (FUJIFILM, Tokyo, 
Japan). The genotyping was screened using a single base 
primer extension assay using ABI PRISM SNaPShot Multiplex 
kit (ABI, Foster City, CA, USA) according to the manufacturer’s 
recommendations. Table 1 shows the primer sequences and 
annealing temperatures used for the SNaPshot assay. The 
polymerase chain reaction (PCR) was performed on an ABI 9700 
ThermalCycler (ABI, Foster City, CA). After amplification, the 
PCR product was purified using shrimp alkaline phosphatase 
(SAP) (USB Corporation, Cleveland, OH, USA) and exonuclease 
I (USB Corporation, Cleveland, OH, USA). One μl of the purified 
amplification products was added to a SNaPshot Multiplex 
Ready reaction mixture containing 0.15 pM of genotyping 
primer for the primer extension reaction. Then, the sequences 
were analyzed on an ABI Prism 3730xl DNA analyzer (Applied 
Biosystems, USA). Analysis was carried out using Genemapper 
software (version 4.0; Applied Biosystems). 
    Statistical analysis was performed with SPSS 12.0 (SPSS Inc., 
Chicago, IL, USA). All values were expressed as mean ± SD. 
Differences in MAP, HR, and QTc interval were determined 
using a paired t-test. Comparisons between the two groups 
were analysed using Student’s t-test or a paired t-test where 
applicable. A P value of < 0.05 was considered significant.
Results
    Ninety-one of 100 patients completed this study. The nine 
patients were excluded from the analysis due to failed intu-
bation on the first attempt or delayed intubation which took 
more than 40 sec. Ninety-one patients (38 men and 53 female, 
age 35.8 ± 9.1, weight 64.3 ± 10.9 kg, and height 166.6 ± 8.7 cm), 
were enrolled into the study. 
    The allelic frequencies of the mutant Gly49 and Gly389 were 
12.6% and 19.8%, respectively. Table 2 shows the baseline values 
of MAP, HR, and the QTc interval of the β1AR-49 and β1AR-389 
gene polymorphism. No differences were found in the baseline 
values of MAP, HR, and the QTc interval for β1AR-49 and β1AR-
389, respectively. Significant increases were detected in MAP, 
HR, and the QTc interval following laryngoscopy and tracheal 
intubation (Table 3). 
    When the percentage change of MAP, HR and the QTc interval 
was examined by genotype immediate after intubation, only in 
β1AR-49, was the change of the QTc interval significantly greater 
Table 1. Primer Sets and Tm for the SNaPshot Assay
β1-AR S49G (rs1801252) β1-AR G389R (rs1801253)
Forward
Reverse
SNP Primer
Tm (
oC)
GACAGCGCTCGGCTCCT
GTAGCGGAAGGGCGAGGT
GCTGAGACAGCGGCTCGGGGC
60
GAGCAGAAGGCGCTCA
GTGGCCCCRACGACATC
TGCGCGCGCAGCAGAGCAGTC
60
Table 2. Baseline Parameters in Patients for β1AR-49 and β1AR-389 
Characteristics
β1-AR Ser49Gly genotype
P
β1-AR Arg389Gly genotype
P
Ser/Ser Ser/Gly Arg/Arg Gly allele
Sex (M/F)
Age (yr)
Height (cm)
Weight (kg)
MAP (mmHg)
HR (bpm)
QTc (msec)
27/41
35.7 ± 9.3
166.4 ± 9.0
63.6 ± 11.0
91.6 ± 11.9
76.4 ± 12.1
368.2 ± 24.4
11/12
36.0 ± 8.7
167.1 ± 8.0
66.7 ± 10.8
89.4 ± 9.9
74.0 ± 13.9
373.3 ± 22.4
0.495
0.898
0.756
0.250
0.432
0.454
0.403
24/35
35.3 ± 9.7
166.4 ± 9.1
64.5 ± 10.4
92.3 ± 11.6
74.5 ± 12.4
370.9 ± 24.9
14/18
36.6 ± 8.1 
166.7 ± 8.1
63.4 ± 12.0
88.8 ± 11.1
78.2 ± 12.7
366.6 ± 22.0
0.777
0.505
0.873
0.641
0.165
0.187
0.436
Data are presented as mean ± SD. Baseline parameters were assessed before anesthesia. MAP: mean arterial pressure, HR: heart rate, QTc: 
corrected QT.
Table 3. Changes in Arterial Pressure, Heart Rate, and QTc Interval
Study variable T0 T1 % change
MAP (mmHg)
HR (bpm)
QTc (msec)
91.0 ± 11.5
75.8 ± 12.6
369.5 ± 23.9
106.6 ± 23.3
101.2 ± 19.9
412.9 ± 28.4
18.4 ± 27.7*
37.8 ± 37.8*
12.0 ± 7.2*
Data are presented as mean ± SD. MAP: mean arterial pressure, HR: 
heart rate, QTc: corrected QT. T0: prior to induction of anesthesia, T1: 
immediately after laryngoscopy and tracheal intubation, % change: 
(T1 - T0) × 100 / T0. *P < 0.001 by paired t-test. 120 www.ekja.org
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in Ser/Ser genotypes than Ser/Gly genotypes. No differences 
were observed immediately after tracheal intubation in the 
change of MAP and HR for β1AR-49 and β1AR-389, respectively 
(Table 4). 
Discussion
    We found that the allelic frequencies of the Gly49 and Gly389 
single-nucleotide polymorphism (SNP) were 12.6% and 19.8%, 
respectively, which were similar to the 15% and 27% found 
in studies on Caucasians (P > 0.05) [8]. The increase in the 
QTc interval was greater in Ser/Ser than Ser/Gly for β1AR-49, 
whereas no difference in the percentage change of MAP and HR 
was observed for β1AR-49 and β1AR-389. 
    In the human heart, β1AR and β2AR coexist, and β1AR pre-
dominates. β1AR actively participates in the regulation of heart 
rate and contractility in cardiomyocytes. The β1AR couples to 
the Gs-protein thereby elevating the intracellular level of cyclic 
AMP and causing positive inotropic and chronotropic effects, in 
vitro as well as in vivo [12].
    Several studies have investigated a possible impact of the 
Ser49Gly and Arg389Gly β1AR polymorphism on resting 
hemodynamics and hypertension, but the results were variable 
[13-20]. The Gly49 variant demonstrated characteristic features 
of a constitutively active receptor. In cells expressing the Gly49 
β1AR, basal and agonist-stimulated adenylyl cyclase activity 
was higher than that of Ser49 β1AR. The Gly49 β1AR was more 
sensitive to the inhibitory effects of antagonists, such as 
metoprolol, and displayed increased affinities for the agonist 
[13,14]. However, other studies on the phenotypic effects of 
the β1AR polymorphism have revealed controversial data. The 
Gly49Gly receptor showed greater long-term agonist-promoted 
down-regulation than the Ser49Ser receptor and subjects 
with Gly49Gly had significantly lower resting heart rates than 
patients carrying the 1 or 2 Ser alleles [15]. In our study, the 
increase of the QTc interval was greater in Ser/Ser than Ser/
Gly for β1AR-49, which was consistent with Paavonen’s findings 
showing that patients with the Ser49Ser genotype had a longer 
QT interval during exercise than patients with other genotypes 
[16]. Our findings suggest that Ser49 homozygotes are more 
active and risky alleles than the other variants in the QTc 
prolongation associated with endotracheal intubation.
    Isoprenaline-induced adenylyl cyclase activation was 3-4 
times higher in the Arg389 receptor than in the Gly389 receptor 
[17]. These differences were due to a greater coupling of the 
Arg389 receptor to the Gs-protein than was found in the Gly389 
receptor. Greater inotropic and cyclic AMP responses to 
catecholamine were reported in Arg389 homozygotes when the 
dobutamine stress test was performed [18,19]. The Arg389 β1AR 
exhibited greater short-term agonist-promoted desensitization 
than the Gly389 β1AR [20]. However, some studies found no 
differences in the increase in exercise-induced heart rates and 
contractility in Arg389- and Gly389 β1AR subjects, whereas 
dobutamine evoked greater increases of heart rate and 
contractility in Arg389- than in Gly389 β1AR subjects [21]. The 
reason for this discrepancy in cardiac responses to exercise with 
dobutamine is not completely understood. However, exercise 
may induce more physiologic responses, which are dependent 
on the physical fitness of the subjects, while dobutamine 
infusion may induce more pharmacologic responses [22]. 
According to our results, no difference in cardiovascular pheno-
types immediately after tracheal intubation was found in β1AR-
389 gene polymorphism. The exact mechanism for this was not 
clear, but the intubation-induced cardiovascular response was 
more similar to exercise-induced cardiovascular change than 
the change due to catecholamine infusion. Our results suggest 
that the Arg389Gly polymorphism of the β1AR made little or no 
contribution to the difference in cardiovascular changes from 
endotracheal intubation during sevoflurane anesthesia. 
    Our study has a limitation in that endotracheal intubation 
was not the only factor that influenced the QTc interval. We 
cannot rule out the effect of sevoflurane on the QTc interval 
prolongation during endotracheal intubation, although no 
differences in the QTc interval before endotracheal intubation 
were found for Ser49Gly and Gly389Arg polymorphism (data 
not shown). Most anesthetic agents, including sevoflurane, 
prolong the QTc interval [23,24], which was consistent with 
the results of this study (data not shown). In this study, 
inhalation induction with sevoflurane was performed without 
pre  medication or intravenous induction agents to avoid the 
com  plicating effect of other anesthetic drugs on the QTc 
interval. This is because the effect of some anesthetics on the 
Table 4. Percentage Change of Mean Arterial Pressure, Heart Rate, and QTc Interval According to the Genotype of β1-AR Polymorphisms
Characteristics
β1-AR Ser49Gly genotype
P
β1-AR Arg389Gly genotype
P
Ser/Ser Ser/Gly Arg/Arg Gly allele
% Increase of MAP
% Increase of HR
% Increase of QTc 
14.7 ± 28.4
33.3 ± 36.5
13.0 ± 7.0
29.9 ± 22.2
51.4 ± 39.5
9.1 ± 7.1
0.067
0.347
0.005
16.6 ± 26.0
39.5 ± 38.4
12.0 ± 6.9
21.6 ± 30.8
34.7 ± 37.1
12.1 ± 7.7
0.886
0.601
0.614
Data are presented as mean ± SD. MAP: mean arterial pressure, HR: heart rate, QTc: corrected QT.121 www.ekja.org
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QTc interval remains controversial. To facilitate endotracheal 
intubation, vecuronium was administered, because it lacks an 
autonomic effect and causes no significant change in the QTc 
interval [25].
    In conclusion, we found an association between the Ser49 
homozygote gene of β1AR-49 polymorphism and increased 
QTc prolongation during endotracheal intubation with 
sevoflurane anesthesia. Thus, β1AR-49 polymorphism may be 
useful for predicting the risk of arrhythmia during endotracheal 
intubation in patients with congenital or acquired long QT 
syndrome. 
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